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Abstract

ASSESMENT OF ANTIBIOTIC RESISTANT GENE EXPRESSION IN
CLINICAL ISOLATES OF PSEUDOMONAS AERUGINOSA
Dustin Esmond
Thesis Chair: Ali Azghani, Ph.D.
The University of Texas at Tyler
August 2021

Increasing prevalence of nosocomial infections by antimicrobial resistant
pathogens resulting in higher mortality rates and financial burden is of great concern.
Pseudomonas aeruginosa represents one of six highly virulent “ESKAPE” pathogens that
exhibit considerable intrinsic drug resistance as well as mechanisms for acquiring further
resistance. As many of these mechanisms are regulated through gene expression, we
sought to identify regulatory strategies and patterns at play in 23 clinical isolates
collected from Baku, Azerbaijan and Tyler, Texas, USA. Real-time quantitative
polymerase chain reaction was performed on six gene targets implicated in resistance and
contrasted with antibiotic phenotypes. We found AmpC cephalosporinase production to

vi

be far less determinant of β-lactam resistance than previously indicated. The relative
expression of the outer membrane porin channel, OprD, appears to have a much greater
influence on phenotype. Both intrinsic efflux pump systems, MexAB-OprM and MexXY,
proved necessary for resistance despite the degree of membrane impermeability. The
induction of the acquired MexCD-OprJ and MexEF-OprN systems were found to
considerably downregulate and impair the intrinsic efflux pump genes and proteins,
respectively. Complex differential gene regulation that was phenotype dependent as well
as highly correlated regulatory expression values continue to suggest higher ordered
mechanisms yet to be understood. In addition, inhibitory overlap between the various
resistance mechanisms supports the need for further expansion of gene targets as well as
the modular response to treatment by P. aeruginosa. Further understanding could provide
exploitation of regulatory feedback loops in which reversion of susceptibility towards
intended agents may be achieved.

Chapter One
Introduction
Background
Pseudomonas aeruginosa (PA) is a Gram-negative, encapsulated bacterium
classified as a facultative anaerobe, which provides it the ability to survive and spread in
a multitude of environmental conditions1. This bacillus pathogen is noted for its
opportunistic behavior of causing infections in immunocompromised patients and
concurrent infections with other microbes2.
Patients with cystic fibrosis (CF) are one of the cohorts greatest affected by
recurrent PA infection. The organism’s metabolic flexibility allows for survival in the
thick layers of mucus located within the lungs of CF patients along with the release of
bacterial byproducts such as pyocyanin pigments which retard the growth of other rival
bacteria3,4. Extracellular projections, such as pili, are present within clinical isolates that
establish antiphagocytic properties and assist in bacterial attachment to host tissues as
well as the production of alginate which acts as a physical barrier to host defenses and
antimicrobial agents5,6. Additionally, the secretion of various products such as
endotoxins, exotoxins, proteases, and hemolytic enzymes contribute to the pathogenicity
and establishment of PA7.Within CF patients alone, roughly 70% of adults exhibit
colonization of persistent PA leading the chronic infections eventually resulting in
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respiratory failure. A significant reduction in life expectancy is observed, with a median
of roughly 40 years survival for affected individuals8. As aforementioned, the hypersecretion of mucus and epithelial cilia clumping associated with abnormalities of the
cystic fibrosis transmembrane regulator (CFTR) protein create an ideal media for the
survival and establishment of PA colonies. Inherent antimicrobial resistance (AMR)
arising from the metabolic flexibility and various defense mechanisms of the organism
result in treatment inefficacy for these patients. Though PA is most significant in CF
morbidity and mortality, it also poses a concern in otherwise compromised individuals.
Presence and Relevance
Ubiquitous in nature, PA is commonly found in but not limited to moist
environments such as soil, water, and vegetation9. Clinically, the organism is isolated
from the skin, throat, and stool of healthy individuals reinforcing its opportunistic
behavior while typically remaining innocuous. Within hospital settings PA colonizes
sinks, taps, and respiratory equipment10. Subsequently, compromised individuals that are
hospitalized are at great risk of developing healthcare-acquired infections (HAIs) through
contact with these surfaces as well as patient-to-patient and healthcare provider-to-patient
transmission via physical contact and fomite vectors11. Given the large amounts of
antimicrobial use in these environments, many of these nosocomial infections represent
strains that already exhibit antibiotic resistance (ABR) to various classes of antibiotics.
Moreover, many of these strains express phenotypes that confer resistance to several
different antibiotics simultaneously, coined multidrug-resistant (MDR) pathogens12.
According to the US Centers for Disease Control and Prevention (CDC), in 2017
roughly 32,600 HAIs among domestically hospitalized patients and 2,700 deaths were
2

attributed to MDR PA infections with an estimated attributable healthcare cost well
exceeding $767 million13. Due to the universal presence of PA coupled with its
increasing prevalence in HAIs, a better understanding of its resistance mechanisms is
needed in order to improve preventative measures and treatment modalities.
Antimicrobial Resistance and Membrane Permeability
Despite being of current concern, the presence of AMR is not a nuanced
observation in PA infection. Clinical isolates obtained from patients as early as 1947,
towards the beginning of antibiotic use, exhibited resistance to streptomycin with quick
adaptation times and higher rates of recurrent infection within those individuals14. As the
majority of antibiotics require diffusion into the cell in order to elicit their intended
effects, initial explanations for resistance were attributed to decreased outer membrane
permeability of the bacteria which prevented uptake in the first place. Subsequently,
various other resistance mechanisms have been described such as the enzymatic
inhibition or cleavage of administered antibiotics, modification of cellular targets, and the
expression of multidrug transporters (efflux pumps) which export antibiotics from inside
the cell to the outside15–17. Since the presence and expression levels of the proteins
implicated in these mechanisms are transcriptionally regulated, induction of AMR can
occur after exposure of PA to treatment agents18. In many cases, the antibiotics
themselves induce gene regulation through binding with transcription factors directly
regulating membrane proteins such as porin channels and efflux pumps19. Antimicrobial
induction of resistance is therefore very important as a widely used practice for treatment
of MDR bacterial infections is the subsequent administration of two or more antibiotics
simultaneously. However, differential diffusion rates of co-administered antibiotics can
3

often lead to exposure of the first agent, giving time for transcriptional regulation to
occur, before the second antibiotic reaches the target site20. Therefore, a better
understanding of the increasing prevalence and interplay of said mechanisms is
paramount in informing future clinical practice and preventing further resistance.
Antimicrobial resistance mechanisms are commonly regulated either globally,
with transcriptional activators that do not need to bind substrates (antibiotic agents) and
induce regulation of the resistance proteins themselves, or locally, in which the substrate
acts as an inducer by binding to proteins implicated in resistance and leading to
regulation21. The primary focus of this study is to assess variable gene expression in
relation to antimicrobial resistant phenotypes observed to various classes of antibiotics,
we will focus on the latter form of regulation.
Active Extrusion
Active efflux pumps responsible for the export of several different antibiotics
comprise one of the major mechanisms responsible for AMR and can typically be divided
into three distinct categories: (a) those of the ATP-binding cassette-type (ABC), (b)
resistance nodulation division (RND) family, and (c) the major facilitator superfamily
(MFS)22,23. In general, ABCs differ in that they utilize ATP hydrolysis in order to export
substrates but typically only of relevance within Gram-positive bacteria. RNDs and MFSs
however export substrates through coupling with proton transport in an antiporter
fashion. Furthermore, these transporters are noted in their ability to export a variety of
structurally unrelated substances leading to their indiscriminate MDR properties24.
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Understanding of the structural properties of PA membranes is necessary at this
point in establishing the location and roles of the various MDR transporters at work.
Cells of PA are comprised of a three-layered cellular envelope which consists of an
inner/cytoplasmic membrane, a peptidoglycan layer, and an outer membrane. Members
of the monomeric MFS are typically located within the inner cytoplasmic membrane
responsible for exporting substrates from the cytoplasm to the periplasm25. As export is
not fully complete, these transporters alone can be insufficient for drug elimination as
periplasmic concentrations remain and also may continue to diffuse back into the
cytoplasm. However, when working in conjunction with proteins located within the outer
membrane, such as fusion and porin channels like OprD, OprJ, and OprM, they can
potentially facilitate complete excretion of harmful substrates26. For the most part, this
family of transporters is regulated locally by direct binding of transcription factors to
toxic compounds exported by the proteins themselves19. Although a contributor to MDR
and representative of a piece of the puzzle in understanding these resistance mechanisms,
MFS transporters are not of primary focus for this thesis but should be kept in
consideration to value potential interplay between efflux systems and generate a holistic
picture of overall processes at play.
The central emphasis of this study, however, are the RND transporters as they are
the largest contributor to non-specific MDR in Gram- bacteria27. These tend to be trimeric
proteins which bind substrates in the periplasm and export them through all three cell
layers using membrane fusion and porin proteins28. One of the best characterized and
referenced RND efflux pumps in PA is that of the MexAB-OprM pump which can be
seen below in Figure 1. The MexA, short for “multidrug efflux”, portion is an efflux
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membrane fusion protein which connects MexB and OprM proteins. MexB refers to the
efflux transporter located within the cytoplasmic membrane responsible for binding the
substrate in the periplasm and beginning outward movement through the pump. Once
these substrates have passed through the MexA fusion protein in the cytoplasm, they are
passed through the outer membrane factor protein OprM effectively exporting them
completely outside of the cell29. These three major proteins work in conjunction to form a
functional transmembrane-spanning RND transporter. A large portion of PA’s inherent
resistance is due to the constitutive expression of this pump, offering a broad and fairly
indiscriminate selectivity for many drugs. Effective export of aminoglycosides, βlactams, and fluoroquinolones are all performed by these RND pumps.

Figure 1: Visual representation of the MexAB-OprM efflux pump system spanning P. aeruginosa
nuclear envelope.
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Like that of MFS pumps, they are subject to local regulation through toxin
binding to initiate transcriptional changes30. Upregulation of genes such as mexA, mexB,
and oprM lead to increased expression of these efflux proteins and typically result in
increased export and subsequent higher levels of resistance to antibiotics they can bind31.
As all three genes that encode these proteins are located on the same operon,
transcriptional control through an upstream regulator, mexR in this case, is responsible for
expression levels seen. Functioning as a repressor, loss of mexR expression leads to upregulation of MexAB-OprM genes increasing active efflux as shown in Figure 2. Similar
efflux systems are present, such as MexCD-OprJ, MexXY-OprM, and MexEF-OprN
which are subject to comparable gene regulation. Unlike the MexAB proteins, the
MexXY pumps are only expressed upon induction due to antibiotic exposure and
typically act on macrolides, tetracyclines, and aminoglycosides. The majority of these
pumps contain all three of their respective genes on the same operon, resulting in fairly
uniform gene expression for their efflux systems.

Figure 2: Upstream control of the MexAB-OprM operon by the transcriptional regulator mexR.

Genes responsible for the regulation of MDR operons of interest are of great
importance in understanding mechanisms at play As MexAB-OprM genes are all located
on the same operon, mexR and nalD act as primary and secondary repressors,
respectively, with increased presence leading to a decrease in pump protein expression32.
Conversely, nalC acts as a positive regulator of the MexAB-OprM operon where
increased presence leads to overexpression of these pumps33. Much in the same fashion
7

as mexR, mexZ functions as a repressor for the MexXY system. As this pump recruits
various members of the porin families such as OprM in order to form a complete
transmembrane-spanning group, only MexXY are regulated together on the same
operon34. This pump is fairly selective, primarily conferring aminoglycoside resistance
but can also exhibit β-lactam resistance depending on the outer membrane porin protein
utilized.
In contrast, regulation of the MexEF-OprN system occurs through the LysR
protein transcriptional activator MexT which positively regulates expression of this
pump35. The mexT gene also acts as a repressor for the OprD porin which is used for cell
entry by carbapenems. Interplay between this system and MexAB-OprM has been
observed, with expression of mexT leading to down regulation of MexAB-OprM36.
Consequently, strains utilizing this pump system typically have high resistance to protein
synthesis inhibiting antibiotics such as chloramphenicol but are highly susceptible to βlactams.
MexCD-OprJ is another efflux pump whose regulation is implicated in other
systems, impairing MexAB-OprM and MexXY function37. The nfxB gene acts as a
negative regulator for this pump, with inactivation leading to overexpression of MexCDOprJ37. This leads to increased antibiotic resistance in some protein synthesis inhibitors
with extreme susceptibility to many aminoglycosides and β-lactam antibiotics. Indirectly,
overexpression of MexCD-OprJ causes major changes in the outer membrane decreasing
both inherent resistance and acquired mechanisms commonly associated with PA.
Though the higher production of these proteins typically confers higher
resistances to respective antibiotics in most cases, an inverse relationship can begin to
8

develop once a certain expression level is reached. In regard to the various pumps as a
whole, increasing the amount present in the membrane will cause resistance to climb until
overabundance of said pumps begin to disrupt membrane integrity and function. This
leads to an increase in membrane permeability and subsequent antibiotic susceptibility19.
Inversely, the outer membrane factor proteins such as OprD which form porin channels,
allowing diffusion of antibiotics into the cell, exhibit higher levels of resistance when
expression is lost. Furthermore, efflux pump systems that recruit these proteins may
become impaired and unable to finish exportation of substrates. With this in mind,
maximum efflux capabilities seem to antagonistically interact with decreased membrane
permeability. Therefore, an apex or balance of sorts must exist in which further
increased/decreased expression of various mechanisms are at an optimal point. Also, as
various types of antibiotics are unequally affected by different resistance strategies,
increased resistance to some classes will have a contrary effect for others38.
Enzymatic Degradation
While active extrusion by efflux pumps are a major component of antimicrobial
resistance, an integral mechanism also employed by PA is that of enzyme production
which cleaves and/or modifies drugs administered. Beta-lactamases are the most
prevalent and well-characterized of said enzymes. These enzymes act through the
hydrolytic cleavage of the four-membered β-lactam ring contained within the β-lactam
antibiotics such as cephalosporins, penicillin, monobactams, and carbapenems39. Though
new generations of these antibiotics have been designed to be less susceptible to βlactamases, the evolution of extended-spectrum β-lactamases (ESBL) including metalloβ-lactamases and carbapenemases have led to a co-evolutionary arms race in which PA
9

has modified these enzymes to remain competitive with new treatments40. AmpC-type βlactamases are special classes of these enzymes which are unique in their ability to
remain active despite the co-administration of β-lactamase inhibitors. The ampC gene is
responsible for expression of these enzymes and similar precursors, with increased
expression conferring higher levels of resistance to respective β-lactams41.
Gene Regulation Ability
P. aeruginosa currently has the largest sequenced genome of any bacteria
consisting of 6.3 million base pairs in total. Similar open reading frame (ORF) sizes and
inter-ORF spacings to that of other large bacterial genomes indicate that recent gene
duplication has not been the cause of PA’s genome size. Further examination has
revealed that PA has considerably higher paralogous gene families than other closely
associated bacteria42. Horizontal gene transfer on mobile genetic elements is thought to
be responsible for these observations43. With these considerations in mind, PA’s ability to
quickly adapt and exhibit resistance to antimicrobials is easily explained due to the high
degree of functional diversity and numerous gene families already present within the
genome. Furthermore, analysis has identified roughly 9% (500) of the genes play roles in
transcriptional regulation and environmental sensing44. As will be discussed in detail,
these findings have critical implications as the three major modes of ABR previously
discussed fall under transcriptional regulation by these genes. With all of our genes of
interest shown below in Table 1 being chromosomally located, assessment of expressed
genes will give insight into regulatory processes in action (please refer to
http://www.pseudomonas.com for additional information).
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Table 1: Gene targets of interest and their respective systems implicated in antimicrobial
resistance.

Gene

Function

System

mexR

Repressor

MexAB-OprM

mexZ

Repressor

MexXY

mexT

Activator

MexEF-OprN

nfxB

Repressor

MexCD-OprJ

oprD

Precursor

Porin Channel

ampC

Precursor

β-lactamase

rpsL

Translation

30S Subunit

As the expression of these proteins is proportional to the amount of their
respective genes being transcribed, for the most part, quantification of said genes should
elucidate which mechanisms are responsible for observed phenotypic resistances45. Realtime (RT) quantitative polymerase chain reaction (qPCR) has been established as an
effective and reliable method for this form of analysis. Although typically used in clinical
settings for identification of resistance, specific gene targeting also allows for the
identification of the regulatory mechanisms at play. Analysis of mutant strains looking at
genes implicated in antimicrobial resistance have shown reliable and reproducible results
utilizing this method31. Variable gene expression has also been used to better understand
resistance mechanisms, though mostly under directed evolutionary approaches in which
strains resistant to a single class of antibiotics are induced and assessed.
In this study, we proposed a more clinically applicable assessment of variable
gene expression across multiple antibiotic classes. Our intentions were to elucidate the
patterns driving multi-drug resistance in P. aeruginosa and how they operate in
11

conjunction with one another. By comparative study of isolates from Baku, Azerbaijan
and Tyler, TX, USA we hope to identify regional differences in emergence of antibiotic
resistance and the underlying mechanisms involved. Through quantitative analysis of the
AmpC β-lactamase, impact on β-lactam antibiotic resistance were assessed. Relative
expression of OprD should shed light on the membrane impermeability’s role in driving
resistance in a non-discriminate manner. Lastly, analysis of the four major RND
transcriptional regulators, MexR, MexT, MexZ, and NfxB, may serve to show their
responsibility in mediating resistance for specific antibiotic classes and combinations.
The institution of a more systematic approach under a broader lens by exploring isolates
from various locations and resistance profiles may help in elucidating potential regulatory
interplay between these mechanisms.
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Chapter Two
Materials and Methods
Sample Collection and Handling
Clinical isolates were procured domestically from The University of Texas Health
Science Center at Tyler containing Pseudomonas aeruginosa (PA) samples collected
from patients of various age, sex, and ethnicity. These were taken from different sites of
infection and cultured to determine their identity as well as establishment of their
respective antibiotic resistance (ABR) antibiograms to ten commonly used antibiotics. A
characterization of susceptible, intermediate, or resistant was assigned in regard to each
antibiotic tested using the Kirby-Bauer method for each isolate utilizing standardized
MIC (minimum inhibitory concentration) ranges46. Samples were then received by the lab
frozen in liquid culture containing Luria-Bertani (LB) broth and glycerol.
International clinical isolates originating from Baku, Azerbaijan were collected by
our collaborators at Azerbaijan Medical School at Baku with subsequent identification
and resistance level determination performed by their clinical laboratories. These samples
were shipped to us in vials containing Luria-Bertani (LB) agar.
Bacterial Subculturing
Samples obtained within liquid culture were thawed and 100 µL of each isolate
were transferred to 14 mL 17x100 mm culture tubes each containing 5 mL
13

of LB broth. Overnight (16hr) incubation was carried out at 37°C while shaking at 200
rpm with closures on but raised to allow aeration. To achieve mid-log phase growth, 200
µL of the resulting culture was added to 3 mL of LB broth and incubated for 8 hr at 37°C
while shaking at 220 rpm. Equal parts culture and sterile glycerol (30%) were combined,
resulting in a 15% glycerol concentration, and 1 mL aliquots were placed in Corning
Cryogenic Vials. These samples were then placed in a -80°C freezer.
International isolates received on culture swabs were plated on LB Agar and
grown overnight at 37°C. Transfer to liquid media was achieved by inoculating 5 mL of
LB broth with individual colonies from the plates using sterile loops. These cultures were
grown overnight and underwent subsequent incubation/cryofreezing utilizing the
aforementioned protocols for liquid cultures.
Preceding RNA extraction, samples were thawed, subcultured overnight and then
subcultured again for 8 hr at 37°C to achieve cells within mid-logarithmic growth for
optimal gene expression.
RNA Extraction
Total RNA was extracted and isolated from bacterial cultures using a columnbased method as part of Qiagen’s RNeasy Protect Bacteria Mini Kit (Germany). Due to
PA’s rigid outer membrane, optional enzymatic lysis was carried out using a 1mg/mL
lysozyme solution in Tris-EDTA (TE) buffer. An on-column DNase digestion was also
performed to remove genomic DNA and endogenous RNases. To increase purity and
remove contaminants, RPE buffer was left to incubate on the column for 3 min before
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centrifugation. RNA was then eluted from the column with two 30 µL RNase-Free water
spins at 9,000 x g for 1 minute each and immediately placed on ice.
RNA Concentration and Purity Determination
In order to assess concentration and purity, spectrophotometry was performed
using a Thermo Scientific NanoDrop 2000. RNA purity values of A260/A280 and A260/A230
were required to both be 1.8 or greater to ensure proper downstream application. RNA
integrity was then verified by Agarose Gel Electrophoresis to observe proper 23S/16S
rRNA bands. A 1% gel containing Ethidium Bromide was ran at 120 V for 70 min in
TAE Buffer before being placed in a UV transilluminator. The gels were exposed and
images were kept for verification. RNA concentrations obtained were then used to dilute
PAO1 lab strain and experimental isolate extracts to 50 ng/µL and stored in individual 14
µL and 70 µL aliquots, respectively, at -80°C for future qPCR application. These aliquots
were performed to reduce possible degradation from repeat thaws and freezes.
Primer Selection and Verification
Established primers from previous literature were selected with amplicon sizes
below 300 bp to provide optimal and consistent qPCR results45. Target genes of interest
represent those implicated in antimicrobial resistance(AMR). As many components of
certain AMR pathways are located within the same operon, upstream regulator genes
were used as targets. Due to their previous characterization, expression of the regulator
should be indicative of the downstream components themselves45. The rpsL gene which
encodes the 30S ribosomal subunit was selected for the housekeeping gene due to its
consistent expression across PA strains, allowing for the normalization of relative gene
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expression. Table 2 lists the target genes, name and sequence of the primers used in this
project47.
Table 2: Forward and Reverse primer sequences for genes of interest implicated in AMR.

Target

Primer

5’ – 3’ Sequence

mexT1

CAGCACCGCGGTGTTCCGCATCG

mexT2

ACGGTCTTGCGCTTGGCGTTGGC

mexZalt1

CCTGGAAAAGGGCGTGGGCA

mexZalt2

AGCACTGGCGGAGAAAGCCC

ampC1

CGGCTCGGTGAGCAAGACCTTC

mexT

Amplicon Size (bp)

216

mexZ

218

ampC

218
ampC2

AGTCGCGGATCTGTGCCTGGTC

mexR1

CGCGAGCTGGAGGGAAGAAACC

mexR

150
mexR2

CGGGGCAAACAACTCGTCATGC

oprD3

CTCGACGGCACCTCCGACAAGAC

oprD

232
oprD4

AGCCCTTCGAATTCGCTGCTCTG

nfxB1

CGCCTGATCAAGGAACACCTCACC

nfxB

164
nfxB2

CGAAACACGCCTTTCTGCTGTCC

rpsL-F

GCAAGCGCATGGTCGACAAGA

rpsL

201
rpsL-R

CGCTGTGCTCTTGCAGGTTGTGA

To ensure reliable quantitative results, primer pairs were optimized for RT-qPCR
using RNA extracted from the PAO1 lab strain. Qiagen’s QuantiNova SYBR Green RTPCR kit was utilized and reaction mixes were prepared according to the manufacturer’s
recommendation. Thermal cycling protocol was performed using a Bio-Rad CFX96
Connect (USA) as follows: 10 min at 50°C for reverse transcription followed by 2 min at
16

95°C for initial PCR activation. Two-step cycling followed consisting of 5 s at 95°C, 10 s
at 60°C with a plate read. This was repeated 39 cycles before a melt curve was
performed. Primers were tested at various concentrations across a 5-fold RNA serial
dilution to determine efficiency. Optimal primer concentrations were determined by
instituting an efficiency range of 95–105% and an R2 ≥ 0.98. To assess primer specificity,
amplicons underwent 1% agarose gel electrophoresis.
RT-qPCR Gene Expression Assessment
Gene expression data was gathered under the aforementioned protocol using 100
ng of RNA per reaction. Seven gene targets, including the housekeeping gene rpsL, were
tested per isolate in quadruplicate. One positive control (PC) and two non-template
controls (NTC) were performed alongside for validation. Mean Cq values obtained were
normalized based on the housekeeping gene’s expression using Bio-Rad’s Normalized
Expression Mode (ΔΔCq). Resulting inter-isolate relative normalized expression values
were then extracted for statistical analysis.
Statistical Analysis
To assess which major mechanisms were responsible for observed phenotypes,
relative gene expressions obtained from RT-qPCR were used. Expression values were
logarithmic (log10) transformed to better represent relative changes in gene expression
and establish normality. IBM SPSS Statistics for Windows, Version 26.0 was used for all
analysis. Pearson’s correlation was performed for all pairwise gene combinations and a
matrix was constructed. Associations between gene regulation patterns and their
interplays could be inferred across isolates for each gene of interest using these findings.
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Observation of inverse expression levels between various genes could provide evidence
of coupled regulatory mechanisms.
Due to the categorical nature of susceptibility classification in our samples,
isolates exhibiting intermediate or resistant phenotypes were combined. Susceptibility
level was therefore considered either susceptible or non-susceptible in isolates for their
respective antibiotics tested. With these dichotomous classifications, point biserial
correlation was performed between continuous expression levels and phenotype for all
isolates.
Lastly, non-transformed relative gene expression values were normalized to
PAO1 and presented alongside their susceptibility profiles. The complex co-regulation
and interplay of these targets, especially in clinical isolates, facilitated the need to analyze
resistance patterns through descriptive statistics of their antimicrobial resistant
phenotypes.
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Chapter Three
Results
RNA Library
Total RNA was extracted from isolates incubated to mid-logarithmic phase using
a column-based method before spectrophotometry analysis was performed.
Concentrations of resulting nucleic acids were determined as shown in Table 3. Ratios of
absorbance at A260/280 and A260/230 were obtained and used for assessment of purity.
Samples included for study exhibited A260/280 ratios between 2.09-2.24, with A260/230 ratios
from 1.86 – 2.48 indicative of pure RNA.
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Table 3: Concentration and Purity assessment of RNA library by spectrophotometry.
Isolate

Conc. (ng/µL)

260/280

260/230

AMR_22

533.4

2.13

2.26

AMR_24

529.6

2.17

2.45

AMR_27

510.2

2.16

2.41

AMR_29

531.5

2.13

2.31

AMR_35

544.1

2.09

2.39

AMR_36

406.5

2.15

2.2

AMR_39

653.4

2.18

2.16

AMR_41

736.7

2.15

2.48

AMR_43

420.9

2.19

2.34

AMR_47

589.1

2.15

2.36

AMR_48

492

2.12

2.13

AMR_49

447.8

2.15

2.43

G1

514.9

2.13

2.35

G3

200.2

2.12

2.22

G5

702.9

2.2

2.32

G8

681.6

2.17

2.32

G9

563.1

2.12

2.34

G14

793.9

2.18

2.31

G17

548.3

2.13

2.39

G18

623.7

2.16

2.34

G21

608.9

2.18

1.86

G24

514.9

2.18

2.4

G26

730.5

2.18

2.46

G30

617.1

2.13

2.45

PAO1.1

467.5

2.17

2.3

PAO1.2

748

2.15

2.35

AMR_29.1

402.9

2.24

1.92

AMR_29.2

419.2

2.17

2.39

a Isolates annotated with “AMR” and “G” originated from Tyler and Baku, respectively.

Agarose gel electrophoresis was then performed on samples meeting purity
thresholds to assess RNA integrity. Presence of distinct bands of 23S/16S rRNA and
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absence of genomic DNA contamination indicate intact RNA for downstream
applications (Figure 3).

G24/30 AMR_24/27

Figure 3: Agarose (1%) gel electrophoresis of 2 µg stock RNA template from each isolate alongside VWR
Ready Ladder 100 bp DNA Marker. A) Laboratory strain PAO1 and AMR_29 were used for primer
optimization and positive controls in qPCR. Experimental samples G24/30 and AMR_24/27 included
alongside. B) From left to right: RNA Samples AMR_22, 29, 35, 36, 39, 41, 43 and 47. C) From left to
right: RNA Samples AMR_48 and 49 in duplicate. D) From left to right: RNA Samples G1, 3, 5, 7
(excluded due to low intensity), 8, 9, 14, and 17. E) From left to right: RNA samples G18, 21, 26.
Remaining wells were not included in the study.
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Primer Verification
RT-PCR was performed on PAO1 RNA extract to assess primer specificity.
Agarose gel electrophoresis of resulting products was carried out as seen below in Figure
4. Presence of a single distinct product at the proper amplicon size was observed for all
gene targets of interest (Table 4).

100 bp
Ladder

500 bp

200 bp

Figure 4: Agarose (1%) gel electrophoresis of RT-PCR products to confirm primer specificity.

Primer Optimization
Primer concentrations were optimized using RNA samples from PAO1 across a
five-fold template dilution series for each target gene. Linear regression was performed
contrasting Cq values with template concentration to produce efficiency (E) curves for
rpsL. These can be seen in Figure 5. At F/R (forward/reverse) primer concentrations of
0.350 µM, an efficiency between 95.0 – 105.0% (99.8%) was obtained with a r2 ≥ 0.980
(0.988) satisfying optimization requirements for the housekeeping gene.
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Figure 5: rpsL efficiency curve at F/R primer concentrations of 0.350 µM.

Subsequent melt peak analysis was performed to further verify primer specificity.
Visual representation of melt peak height is shown in Figure 6 as the negative derivative
of cycling temperature against fluorescence. Presence of one unique product is indicated
by the single melt peak at 85.5°C.
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Figure 6: Primer specificity verification of rpsL by melt peak analysis following optimization.

The aforementioned analyses were performed for the remaining genes of interest
to determine their respective primer concentrations. Efficiency curves and melt peaks can
be seen in Figure 7. All primer targets exhibited efficiencies of 95.0 – 105.0% with r2 ≥
0.980. Due to the induced nature of mexZ expression, inadequate presence in PAO1
resulted in poor optimization. Therefore, experimental isolate AMR_29 template was
used to complete mexZ analysis. Summary of the data from optimization is shown in
Table 4.
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A)

B)

C)

D)

E)

F)

Figure 7: Efficiency curves and melt peak analyses for primer optimization of gene targets of interest. A)
mexT at 0.400 µM. B) mexZ at 0.400 µM. C) ampC at 0.500 µM. D) mexR at 0.300 µM. E) oprD at 0.300
µM. F) nfxB at 0.500 µM.
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Table 4: Primer optimization results for genes of interest.

Gene Target F/R Primer Conc. (µM) Efficiency (%)

r2

Melt Peak Temp. (°C)

mexT

0.400

102.1

0.988

89.0

mexZ

0.400

96.6

0.991

87.5

ampC

0.500

99.8

0.981

89.0

mexR

0.300

103.9

0.993

86.5

oprD

0.300

104.8

0.987

89.0

nfxB

0.500

99.1

0.987

86.0

rpsL

0.350

99.8

0.988

85.5

Assessment of Phenotypic Antimicrobial Resistance
Antibiograms were performed on each clinical isolate by our collaborators against
several commonly used antibiotics. A total of 23 isolates were assessed with 12
originating from Tyler and the remaining 11 from Baku. Among multidrug resistant
strains, MIC categorization allowed for the phenotypic determination of susceptibility
against commonly used antibiotics (Table 5). Of the aminoglycosides, both Amikacin (n
= 11) and Gentamicin (n = 23) showed high prevalence of resistance within 36.4% and
43.5% of isolates, respectively. Contrarily, 91.7% of isolates were susceptible to
Tobramycin (n = 12) while 0.0% showed resistance.
Susceptibility to β-lactams also showed considerable resistant prevalence with
56.5% and 52.2% of isolates being resistant to Aztreonam (n = 23) and Ceftazidime (n =
23), respectively. Cefepime (n = 23) showed the lowest number of resistant isolates
relatively while still having 39.1% of isolates exhibit resistance. Of note, Ceftazidime
was not found to have any isolates displaying intermediate susceptibility. Lastly,
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Ciprofloxacin (n = 23) resistance was found in nearly half (47.8%) of all clinical isolates
tested.
Table 5: Overall antibiotic susceptibility phenotypes of MDR strains observed across both Tyler,
TX and Baku, AZ.

Antimicrobial Phenotype (%)
Susceptible Intermediate Resistant
Amikacin*
45.5
18.2
36.4
Aminoglycosides Gentamicin
47.8
8.7
43.5
*
Tobramycin
91.7
8.3
0
Aztreonam
26.1
17.4
56.5
Cefepime
43.5
17.4
39.1
Β-lactams
Ceftazidime
47.8
0
52.2
Meropenem
39.1
13
47.8
Pip/Tazo
43.5
13
43.5
Quinolones
Ciprofloxacin
34.8
17.4
47.8
Agent Tested

a n=23.*Amikacin (n=11) and Tobramycin (n=12) were only tested in Baku and Tyler, respectively.

Phenotypic profiling of isolates from Baku (n=11) alone can be seen in Table 6. It
is of note that of the eight antibiotics tested, no isolates showed intermediary resistance to
six of the agents. Additionally, of these six agents, resistance was shown in more than
half of all isolates. Resistant phenotypes towards Ciprofloxacin and Meropenem
specifically were found to be as high as 72.7 and 81.8%, respectively.
Table 6: Antibiogram distribution of isolates collected from Baku.

Baku
Antimicrobial Phenotype (%)
Antibiotic
Tested
Susceptible Intermediate Resistant
Amikacin
45.5
18.2
36.4
Gentamicin
36.4
0.0
63.6
Aztreonam
27.3
18.2
54.6
Cefepime
45.5
0.0
54.6
Ceftazidime
36.4
0.0
63.6
Meropenem
18.2
0.0
81.8
Pip/Tazo
45.5
0.0
54.6
Ciprofloxacin
27.3
0.0
72.7
a n=11.
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Variable Gene Expression Analysis
RT-qPCR analysis was performed on clinical isolates obtained for the six genes of
interest and normalized based on the rpsL reference gene to assess differential expression
values based on resistant profiles. Gene expression values were log10 transformed for
normality and pairwise correlation was performed between each gene target. This
analysis was performed for isolates of interest overall as seen in Table 7. Statistically
significant positive correlations (p < 0.01) were found between all pairwise comparisons
excluding combinations with oprD. Expression levels of ampC, mexR, mexT, and nfxB
genes showed very high positive correlations (r ≥ 0.812) while exhibiting moderately
positive correlations with mexZ expression (r = 0.606 to 0.657). All pairs with oprD were
negatively correlated; the only statistically significant finding was a moderately negative
correlation between mexZ and oprD. (r = -0.442, p = 0.04)
Table 7: Overall Pearson’s Correlation matrix of gene expression in targets of interest.

ampC
mexR
mexT
mexZ
nfxB
oprD

ampC
1

mexR
0.812**
1

mexT
0.849**
0.935**
1

mexZ
0.606**
0.630**
0.644**
1

nfxB
0.898**
0.928**
0.932**
0.657**
1

oprD
-0.263
-0.124
-0.118
-0.442*
-0.141
1

a n=23. Values in bold are significant with a p ≤ 0.05 (2-tailed). **Correlation is significant at the 0.01
level. *Correlation is significant at the 0.05 level.

To determine if certain correlations were driven by isolates of different origin, a
separate analysis was performed on samples from Tyler and Baku, as seen in Tables 8
and 9. Statistically significant correlations (p < 0.01) found between ampC, mexR, and
mexT were maintained within geographical subsets similar to those found overall with
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slightly higher positive associations seen from Baku. Clinical isolates from Baku
continued to exhibit significant positive correlations between ampC, mexR, mexT, mexZ,
and nfxB consistent with overall results. A moderately negative correlation (r = -0.649, p
= 0.04) was found between ampC and oprD not previously seen overall.
While a consistent moderately positive correlation (r = 0.594, p = 0.05) was seen
between mexR and mexZ, all other comparisons to mexZ were insignificant in isolates
from Tyler. Strong positive correlations (p < 0.01) were maintained between ampC,
mexR, mexT, and nfxB such as those found overall. Correlations between all target genes
and oprD failed to exhibit significance.
Table 8: Pearson’s Correlation matrix of gene expression in targets of interest from Tyler.

ampC
mexR
mexT
mexZ
nfxB
oprD

ampC
1

mexR
0.785**
1

mexT
0.840**
0.936**
1

mexZ
0.396
0.594*
0.493
1

nfxB
0.862**
0.930**
0.939**
0.504
1

oprD
-0.094
0.183
0.110
-0.453
0.075
1

a n=12. Values in bold are significant with a p ≤ 0.05 (2-tailed). **Correlation is significant at the 0.01
level. *Correlation is significant at the 0.05 level.

Table 9: Pearson’s Correlation matrix of gene expression in targets of interest from Baku.

ampC
mexR
mexT
mexZ
nfxB
oprD

ampC
1

mexR
0.917**
1

mexT
0.913**
0.936**
1

mexZ
0.796**
0.660*
0.745**
1

nfxB
0.976**
0.938**
0.929**
0.764**
1

oprD
-0.649*
-0.552
-0.448
-0.426
-0.546
1

a n=11.Values in bold are significant with a p ≤ 0.05 (2-tailed). **Correlation is significant at the 0.01
level. *Correlation is significant at the 0.05 level.
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Point biserial correlation was then performed contrasting gene expression values
and antibiotic resistance phenotypes. To facilitate this, isolates exhibiting intermediate
resistance to antibiotic classes were folded in with those showing resistant phenotypes.
Resulting “susceptible” and “non-susceptible” classifications were generated for each
isolates’ resistance to each antibiotic tested and analyzed against genes of interest.
As shown below in Table 10, statistically significant (p < 0.05) correlations were
observed between Gentamicin and Tobramycin with mexZ in a moderately positive
manner. With this association, mexZ expression is observed to increase in isolates
exhibiting Gentamicin resistance as seen in Figure 8. Expression of oprD exhibited a
medium negative correlation with Tobramycin approaching significance (p = .07). It is of
note that Tobramycin antibiograms were only performed on isolates from Baku and their
analysis is subsequently only indicative of that location. Remaining analyses failed to
identify any further significant correlations.
Table 10: Point Biserial Correlation contrasting gene expression with antibiotic resistance for all
isolates.
ampC
mexR
mexT
mexZ
nfxB
oprD

Location

Amikacin

Gentamicin

Tobramycin

Aztreonam

Cefepime

Ceftazidime

Meropenem

Pip/Tazo

Ciprofloxacin

-0.068

-0.06

0.097

-0.225

-0.216

0.175

0.021

0.178

-0.045

0.25

-0.054

-0.223

0.097

-0.033

-0.206

-0.048

-0.22

0.224

-0.234

0.201

-0.063

-0.354

0.083

-0.12

-0.203

0.091

-0.12

0.264

-0.214

0.25

-0.2

-0.092

0.422*

0.643*

-0.034

0.031

-0.136

-0.001

-0.005

0.256

-0.076

-0.097

0.137

-0.169

-0.237

0.075

-0.056

0.19

-0.112

0.235

0.103

-0.391

-0.306

-0.54

-0.248

-0.093

-0.145

0.021

-0.29

0.112

a *Correlation is significant at the 0.05 level (2-tailed).
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*

Figure 8: Box and Whisker plot illustrating the increase of mexZ expression in Gentamicin
resistant clinical isolates (n=23). *Correlation is significant at the 0.05 level (2-tailed).

Antibiotic susceptibility and relative gene expression values (normalized
around lab strain PAO1) are given for all isolates analyzed in Table 11.
Production of the β-lactam degrading AmpC cephalosporinase was assessed in
relation to resistance observed. The majority of isolates found to have decreased
expression of ampC actually exhibited nonsusceptibility (NS) to β-Lactams with
7/8 isolates resistant to Aztreonam having decreased expression. However, 10/15
isolates with increased expression of ampC did show NS as expected. Cefepime
resistance was found in 9/15 isolates with increased ampC expression. Of these, 7
isolates also showed a decrease in oprD porin expression concurrently. In those
still showing susceptibility (S) despite having increased ampC expression, oprD
was found to be upregulated in 4/6 isolates. Isolates resistant to Ceftazidime with
increased ampC expression also showed a decrease in oprD levels in 6/7 isolates.
This pattern was maintained in 8/11 isolates resistant to Meropenem.
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Piperacillin/Tazobactam resistant isolates with elevated ampC levels also showed
6/8 isolates to have oprD reduction. Interestingly, 12/15 isolates resistant to
Ciprofloxacin also showed increased ampC levels.
Decreased or lost oprD expression was seen in the majority of NS to all
antibiotics tested. Of the aminoglycosides, Gentamicin resistance was found in
9/13 isolates with decreased oprD levels. Susceptibility was seen in 7/10 isolates
with increased expression as expected. In regard to β-lactams, 12/13 isolates
showing decreased porin expression were resistant to Aztreonam. This trend was
consistent across the family with the majority of isolates still found to be
susceptible having increased expression of the mexR repressor and ampC. Greater
than 10-fold reduction in oprD expression, suggestive of total loss, was seen in
5/6 isolates resistant to Aztreonam and Piperacillin/Tazobactam. Lastly, 8/13
isolates with decreased oprD expression showed NS to Ciprofloxacin. However,
7/10 isolates with increased expression still exhibited NS. Five of said isolates
exhibited increases in both ampC and mexZ expression.
In a similar manner, NS to all families of antibiotics tested was found in
the majority of isolates with decreased expression of nfxB. For those exhibiting
susceptibility despite decreased levels of nfxB, down regulation of mexR, ampC,
and mexT was found in nearly all isolates. Also, in those isolates found to be
resistant to said antibiotics despite increased nfxB expression, oprD expression
was decreased in the vast majority. These patterns regarding nfxB regulation
showed remarkable differences between antibiotics or their classes.
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Table 11: Summary data of variable gene expression normalized to PAO1 in 23 clinical isolates
along with antibiotic resistance classification.
Isolate

GEN

TOB

ATM

FEP

CAZ

MEM

TZP

AMR_22

S

S

NS

NS

S

NS

AMR_24

S

S

S

S

S

S

AMR_27

S

S

NS

NS

NS

AMR_29

NS

S

NS

NS

AMR_35

S

S

S

AMR_36

NS

S

AMR_39

NS

NS

AMR_41

S

S

AMR_43

S

AMR_47
AMR_48
AMR_49
G1

AMK

NS

CIP

ampC

mexR

mexT

mexZ

nfxB

oprD

NS

S

1.761

1.717

0.806

1.424

0.894

2.486

S

NS

0.394

0.377

0.498

0.262

0.202

1.741

NS

NS

S

0.651

0.404

0.337

0.521

0.239

1.610

NS

NS

NS

S

7.329

2.105

3.479

6.545

3.761

0.001

S

S

S

S

NS

11.679

5.457

5.809

13.187

4.861

6.905

S

S

S

S

S

NS

2.751

1.751

2.011

3.554

2.702

3.779

NS

S

S

S

S

NS

0.549

0.952

0.662

48.194

0.371

0.001

NS

NS

NS

S

NS

S

0.958

0.707

0.804

1.945

0.856

0.018

S

NS

NS

NS

S

NS

NS

9.671

0.629

0.708

3.146

0.582

0.009

NS

S

NS

NS

S

NS

S

NS

1.599

1.211

1.949

1.636

0.501

0.652

NS

S

NS

S

S

S

NS

S

0.096

0.220

0.093

0.058

0.062

0.431

S

S

NS

NS

NS

NS

NS

NS

82.723

3.075

3.946

4.765

2.976

4.516

S

NS

S

NS

S

S

S

0.249

0.256

0.085

0.081

0.091

1.034

G5

S

S

NS

NS

NS

NS

NS

S

0.283

0.209

0.340

0.678

0.065

0.000

G8

NS

NS

NS

NS

NS

NS

NS

NS

1.183

0.539

0.602

10.542

0.552

0.233

G9

NS

NS

NS

NS

NS

NS

NS

NS

1.510

0.780

0.671

2.280

0.845

0.400

G14

NS

NS

NS

NS

NS

NS

NS

NS

1.375

1.579

0.977

2.646

0.784

0.421

G17

S

S

NS

S

S

NS

S

NS

1.774

3.608

3.694

1.082

1.518

0.505

G18

S

NS

NS

NS

NS

NS

S

S

8.555

7.813

12.276

12.224

7.003

0.297

G21

NS

NS

S

S

S

NS

NS

NS

7.037

4.551

3.618

5.249

3.414

0.001

G24

S

S

S

S

S

S

S

NS

1.033

0.784

1.053

1.946

0.776

5.708

G26

S

NS

S

S

S

NS

S

NS

1.018

0.683

0.436

1.477

0.354

2.774

G30

NS

NS

NS

NS

NS

NS

NS

NS

0.665

0.204

0.307

0.389

0.251

1.967

a AMK=Amikacin, GEN=Gentamicin, TOB=Tobramycin, ATM=Aztreonam, FEP=Cefepime,
CAZ=Ceftazidime, MEM=Meropenem, TZP=Pip/Tazo, CIP=Ciprofloxacin, S=Susceptible,
NS=Non-susceptible. b Isolates annotated “AMR” and “G” represent those collected in Tyler and
Germany, respectively.
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Chapter Four

Discussion
Despite the monumental advances made in antimicrobial development and
treatment, pathogen resistance continues to increase in severity and prevalence. The
increasing financial burden coupled with the inability to prevent mortality in patients
presents us with a concerning future if not addressed quickly. Many have predicted that
the overuse and non-indicated administration of antibiotics has ushered us closer to a
post-antibiotic era in which the emergence and dominance of multidrug resistant (MDR)
pathogens will be unaffected by current treatment48. One could contend that we have
created a co-evolutionary arms race which we seem to be losing. If we hope to combat
the proliferation of antimicrobial resistance (AMR) then it is paramount we understand
not only the mechanisms and strategies utilized by these pathogens but also take a look at
ourselves and identify anthropomorphic actions which may be contributory.
To date the majority of gene regulation studies of P. aeruginosa (PA) in relation
to antibiotic resistance have been performed with mutant laboratory strains49,50. Though
necessary and informative, utilizing a reductionist approach into how exposure to a single
antibiotic can affect gene expression levels or vice versa in otherwise naïve strains does
not give insight into the complex regulatory interplay of resistance mechanisms that
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occur in clinical isolates. Furthermore, clinical isolates of concern commonly present
resistance to multiple antibiotics, further complicating analysis and treatment strategies51.
Longitudinal analysis of PA clinical isolates from 1999 to 2002 found 24.9% of samples
to have MDR phenotypes, with increasing prevalence seen yearly52. The failure to
properly identify the mechanisms present in infection can lead to the incorrect antibiotic
administration. Patient outcomes are not only poor but this provides a pressure which
initiates further resistance due to inducible regulatory elements53,54.
β-lactam Resistance and AmpC Production
Increasing β-lactam resistance, more specifically carbapenem, has been a large
concern and area of focus over the past few decades55–58. Antibiogram findings from our
study showing non-susceptible (NS) phenotypes in more than half of all isolates to this
class echoes those fears. Even more concerning, 81.8% of isolates originating from Baku
were resistant to Meropenem. This is in line with a recent 2021 study in which 63% of
clinical isolates from burn victims in Azerbaijan exhibited carbapenem resistance59.
Spatial and clinical differences continue to highlight driving factors selecting for these
patterns which need to be addressed. As PA’s chromosomally encoded and inducible
AmpC cephalosporinase allows for the hydrolytic cleavage of this antibiotic class, the
regulation of this pathway is very important for our understanding. AmpC production has
been shown to be constitutively expressed at low levels in naïve strains which can then be
rapidly upregulated in response to drug exposure41. This upregulation has been found to
have a direct/causative association with decreased susceptibility to β-lactams.
Increased production of AmpC is well established as the primary means for
observed resistance in this drug class by laboratory studies60. However, such a
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relationship has yet to be solidified in the carbapenem subclass of β-lactams. AmpC
enzyme overproduction was previously thought to be responsible for Doripenem and
Imipenem resistance but did not have the same effect on Meropenem, showing variation
of action within members of the group themselves61. This was reinforced by several
laboratory studies which showed absence of AmpC production resulted in strains
susceptible to carbapenems (except Meropenem)62,63. Subsequently, AmpC expression
levels have been thought to be the primary culprit in β-Lactam resistance until recently.
In direct contrast to previous findings, AmpC knockouts have been observed in
carbapenem resistant strains despite low or undetectable enzyme presence64. Several
studies investigating clinical isolates have found overproduction of AmpC results in
many strains still being susceptible to carbapenems65. Furthermore, clinical isolates
exhibiting resistance to carbapenems were found to have increased AmpC enzyme
production in only half of the resistant isolates66. These new findings have cast doubt on
the previous notion that AmpC is primarily responsible for this class of resistance.
Instead, complex and ordered interplay with OprD porin channel and efflux pump
expression appears to work alongside ampC gene regulation in determining antibiotic
resistance phenotypes.
Our findings support the notion that AmpC may not play as large of a role in βlactam resistance as previously thought. The majority of our isolates with decreased
expression of ampC were still NS to this drug class. Aztreonam NS was seen in 87.5% of
isolates despite ampC reduction. Non-susceptibility under these conditions were also
observed in 62.5% of isolates against Ceftazidime, Meropenem, and
Piperacillin/Tazobactam. If AmpC was the main mediator of β-lactam resistance we
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would expect to see far more susceptible isolates. Furthermore, isolates exhibiting
increased ampC expression levels only showed reduced susceptibility in a slight majority.
Only 46.7% of isolates showed NS to the cephalosporin Ceftazidime despite increased
enzyme expression. The overexpression of ampC alone does not seem to fully explain NS
phenotypes towards β-lactams, supporting the notion of an interplay between resistance
mechanisms yet to be alluded.
Enzymatic Degradation and Membrane Impermeability Interplay
Clinical studies performed in Azerbaijan also saw 75% of carbapenem resistant
isolates having oprD loss while only 25% had AmpC overproduction, in conjunction with
our findings59. This is evident upon analysis of AmpC overproducers resistant to βlactams in which oprD was downregulated in almost all isolates. For example, 8/10
Aztreonam resistant isolates with increased ampC expression also exhibited decreases in
oprD, a trend seen amongst all β-lactams. These findings continue to highlight the
complexity of PA resistance mechanisms as well as their non-mutually exclusive nature.
Previous investigations into transcriptional regulation of OprD after carbapenem
exposure were “… unexpected and suggested a chaotic, unpredictable regulatory
mechanism.67” When β-lactamase production is insufficient in generating resistance
alone, coupled loss of OprD appears to help drive the resistant phenotype. The inverse
also appears to occur in which the majority of isolates susceptible despite increased
ampC expression were found to have increased oprD expression. Increased membrane
permeability could facilitate the influx of carbapenems faster than β-lactamase
inactivation can occur63. With OprD upregulation able to compensate and overcome
enzymatic inactivation of carbapenem resistance, it seems questionable that AmpC is the
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primary phenotype determinant. These findings are much more in line with a
multifaceted view on resistance regulation. Interestingly, Meropenem resistance appears
to follow the same expression patterns despite the lack of connection with AmpC.
Similar observations have also suggested that the current explanations for
established mechanisms do not fully explain the substrate specificity between AmpC and
porin channel proteins68. Loss of oprD expression was found in 72.7% of isolates
resistant to Meropenem with increased expression of ampC. This may explain the
unexpected association of AmpC production with Meropenem non-susceptibility. Though
fluoroquinolone resistance is not mediated through AmpC, 80% of isolates with increased
levels of ampC exhibited resistance to Ciprofloxacin. However, more than half of these
saw decreased expression of both nfxB and oprD, further reinforcing the interplay and
role of membrane permeability in driving resistance.
OprD and Membrane Permeability Influence
If we focus directly on oprD expression patterns, the effect of membrane
impermeability on driving resistance becomes ever more so apparent. Non-susceptibility
was present in the majority of all antibiotics tested within isolates of decreased oprD
expression. Aztreonam resistance was seen in 92.3% (12/13) of isolates with decreased
oprD expression. For the remaining susceptible isolate, increased mexR and nfxB
expression were present and in line with previous findings of MexCD-OprJ specificity69.
The expression of mexT was also found to be upregulated, consistent with its antagonistic
downregulation of OprD as previously described36. In line with this observation, mexT
levels were reduced in the majority of isolates with increased OprD production
corroborating the regulatory function noted. Also, upregulation of mexR in susceptible
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isolates to Cefepime and Piperacillin/Tazobactam was seen in 75% of isolates despite
OprD loss. Expression of the MexAB efflux system and their respective outer membrane
porin channel appear necessary to confer resistance through active extrusion even when
permeability is lowered. Some basal level of transport seems required despite other
mechanisms which is in line with PA’s intrinsic resistance strategies. The presence of
both mechanisms are thought to be the greatest determinant of resistance and in
agreement with our findings70. In the same fashion, mexZ overexpression was found to
mitigate OprD loss and allow susceptibility to Ceftazidime, Meropenem,
Piperacillin/Tazobactam, and Ciprofloxacin in 80% of isolates. Again, Ciprofloxacin
resistance was observed in 7/10 isolates despite increased oprD expression. Seventy-one
percent of these exhibited overproductions of AmpC in line with earlier observations.
This continues to reinforce the complex regulatory mechanisms mediating these major
non-mutually exclusive pathways and solidifies that decreased permeability alone is
insufficient in maintaining resistance without active drug extrusion.
Efflux Pumps and Their Complex Interactions
The MexAB-OprM efflux system remains a central focal point for intrinsic AMR
in PA thanks to its constitutive nature combined with its potential to acquire further
resistance. Its ability to extrude mostly all antibiotics except for Imipenem and
aminoglycosides represents a major component in resistance. Along with the intrinsic
MexXY-OprM system, responsible for aminoglycoside removal, these two pumps
provide PA with a built-in starting point for decreasing susceptibility71. In addition, the
two major inducible efflux systems, MexEF-OprN and MexCD-OprJ, provide further
resistance to fluoroquinolones and certain cephems. While this can be beneficial, both of
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their regulatory mechanisms and expressions have been shown to impair and/or
downregulate the two intrinsic pumps72,73. The positive regulator, MexT, for the MexEFOprN system has further been shown to down regulate OprD while its impairment of the
MexAB system leads to β-lactam hypersusceptibility35. The repressor of the MexCDOprJ pump, NfxB, has been shown to have the same effect as well on MexXY
impairment leading to Gentamicin, Aztreonam, and carbapenem resistance74.
Derepression through downregulation of mexR was seen in roughly half of all
isolates exhibiting resistance to any antibiotic tested. Of these isolates, all but one showed
concomitant mexT downregulation. For isolates with upregulation of mexR, the inverse
was also true suggesting that MexAB impairment resulting from MexEF expression may
be a result of regulatory control as opposed to protein functionality or the use of alternate
mechanisms as previously described75. This is further supported by our gene expression
findings in which mexR and mexT showed a highly positive correlation (r =.935) across
all isolates. Therefore, it seems probable that there exists a direct regulatory interaction
between mexT and mexR76. For both Gentamicin and Meropenem, only 46% of isolates
exhibited NS phenotypes with decreased mexR consistent with MexAB specificity for βlactams excluding carbapenems77. Interestingly, NS was also seen in the majority of βlactams despite increased repression of the MexAB-OprM system. Upon closer
examination, all of these isolates also had increased expression levels of ampC as well as
mexZ. β-lactamase overproduction appears to act in a compensatory fashion to mitigate
loss of active extrusion from MexR repression. The increased repression of the MexXY
efflux system suggests a global regulatory cost for the specialization toward β-lactam
resistance in these isolates. The high degree of regulatory correlation between the
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MexAB and MexXY systems were consistent with prior observations of concomitant
overproduction of each within the same isolates78.
In all isolates exhibiting susceptible phenotypes towards Gentamicin, Aztreonam,
and Meropenem despite loss of repression through MexR, loss of NfxB was also
observed in our isolates. Impairment of MexAB and MexXY systems along with
reduction in ampC expression resulting in hypersusceptibility to these antibiotics
previously described is supported here69. Furthermore, decrease in nfxB expression was
seen in all isolates exhibiting susceptibility towards any antibiotic despite loss of MexR.
These findings suggest the acquisition of MexCD-OprJ can strongly revert intrinsic
mechanisms already present in PA. As these same patterns emerge through the MexT
regulator are present and lead to impairment of the other intrinsic MexXY efflux system,
specific resistant phenotypes can be thought of as potentially transient79. Previous
analysis of mature and established PA colonies has shown the preference of generalized
and well-rounded resistance strategies as opposed to hyper specialization towards any
specific mechanism/drug therapy80. Utilizing this strategy provides more room for
versatility and adaptation upon exposure to new therapeutics but lends them open to
susceptibility when treatment regiments targeting specific weaknesses are implored.
Summary, Implications and Future Directions
Initial identification of not only ABR phenotypes but the underlying mechanisms
being utilized are paramount in clinical settings. As many of these mechanisms arise only
upon induction, and can be maintained by continued drug administration, this information
can not only prevent further resistance but also inform drug choice81,82. The importance
of follow-up antibiogram analysis is abundantly clear as exposure to new courses of
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treatment may impair previous resistance mechanisms, lending isolates once again
susceptible to certain antibiotics. Such exploitation of specificity and interplay may also
be valid strategies in clinical practice. For instance, isolates exhibiting high levels of
resistance through the intrinsic MexAB and MexXY systems may revert to susceptibility
following exposure to fluoroquinolones that upregulate the acquired systems. A temporal
approach to chronic resistance may be appropriate based on these findings.
Overall, extremely high correlation of gene expression in these major regulators
clinically continue to elucidate the highly ordered and complex nature of PA’s resistome.
As direct correlation between gene expression and antibiotic phenotype was only
identified in one pairwise combination, mexZ and Gentamicin, we must acknowledge that
a deeper and wider look into these mechanisms is necessary. Though relative gene
expression analysis can give some insight into various resistance patterns being utilized,
they do not tell the entire story. Many of the genetic mutations which can occur in
various regulators and proteins implicated in resistance lead to changes in phenotype
without variation in their transcription50. Future studies taking advantage of more robust
methods, such as RNAseq, would provide useful in identifying differentially regulated
genes which may correspond to global control elements. Many of the mechanisms of
resistance explored here are suggested to have alternative means of regulation which
could be identified. Since mutational changes in PA can often lead to alteration in protein
functionality without transcriptional control, DNA sequencing of target regions coupled
with protein assays may explain mechanisms not fully understood from the transcriptome
alone.
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In summary, prevalence and severity of antimicrobial resistance in Pseudomonas
aeruginosa continues to rise while our ability to connect genomic information with
protein expression and function is still lacking. This is only further complicated by the
disparities observed between laboratory strain findings and actual clinical isolate patterns.
Our findings suggest AmpC production to be far less determinant in clinical settings on
β-lactam resistance and that OprD interplay appears to have a stronger influence. Overall,
changes in membrane permeability appear to be the most explanatory for observed
phenotypes. Efflux pump system findings were in agreement with their substrate
specificity from previous classifications. Interplay was greatly observed between efflux
regulators, suggesting a venue for exploitation for future treatment and establishing the
need for continued antibiogram monitoring. Intrinsic resistance mechanisms often
assumed in P. aeruginosa treatment have the potential to be reverted and should not be
overlooked. These findings reinforce the presence of an ordered and complex regulatory
control system whose classification could greatly advance our understanding of resistance
establishment. The addition of more gene targets and isolates using a high throughput
method such as RNAseq could help identify other genes implicated in resistance and
understand their roles. Such findings would help inform clinical practice for current
therapy regiments as well as provide potential targets for future pharmacological
development.
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